IMR Press / EJGO / Volume 27 / Issue 4 / pii/2006184

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Jun and Fos family protein expression in human breast cancer: Correlation of protein expression and clinicopathological parameters

Show Less
1 Department of Obstetrics and Gynecology, Division of Senology, Medical University of Vienna, Austria
2 Ludwig Boltzmann-Institute of Clinical Experimental Oncology, Vienna, Austria
3 Department of Obstetrics and Gynecology, LKH Villach, Villach, Austria
4 Department of Pathology, Austria
5 Department of Dermatology, Division of General Dermatology, Austria
6 Department of Medicine I, Division of Oncology, Medical University of Vienna, Austria
Eur. J. Gynaecol. Oncol. 2006, 27(4), 345–352;
Published: 10 August 2006

Objectives: The activator protein-I (AP-I) is a dimeric transcription factor formed by members of the Jun and Fos protein family. AP-I plays a role in a variety of physiological functions including cell proliferation and differentiation, although both c-Jun and c­Fos have also been implicated in oncogenic transformation and tumor progression. To further elucidate the role of AP-I in breast cancer, we have investigated the expression of the AP-I proteins c-Jun, JunB, JunD, phosphorylated c-Jun, c-Fos, Fral, Fra2 and the tumor supressor protein p53. Methods: Protein expression was evaluated on a breast cancer tissue microarray with 58 lymph node positive or negative breast cancer specimens, 29 corresponding lymph node metastases, and 11 tissue samples from surrounding tumor-free tissue, each cored as triplicate. Jun and Fos protein family expression was evaluated by immunohistochemistry and was correlated with clinicopatho­logical parameters. Results: High expression levels were observed for c-Jun, JunD, c-Fos and Fra2, whereas JunB and Fral exhibited lower staining. c-Jun protein expression was correlated to Fral staining (p = 0.007, Kendall's Tau) and Fral was further associated with c-Fos (p < 0.001), JunD (p = 0.001) and Fra2 (p = 0.011) expression. JunD expression correlated with c-Fos (p < 0.001), JunB (p = 0.035) and c-Jun (p = 0.05). Activated c-Jun correlated with c-Fos expression (p = 0.041). JunB was negatively correlated to tumor stage, (p = 0.093, corr coeff. = -0.293, Spearman's correlation) but was significantly increased in nodal negative tumors (p = 0.004, Mann Whitney test). In addition, increased Fral expression showed a trend towards an increased overall survival (p = 0.077, RR= 0.534, Cox regression). Conclusion: Our results suggest an important role for JunB and Fral in the biological behavior of malignant breast tumors.

Breast cancer
Back to top